The Institute for Clinical and Economic Review (ICER) issued a draft evidence report assessing the cost effectiveness of Orchard Therapeutics Limited’s gene therapy for metachromatic leukodystrophy (MLD) ahead of its US market debut, giving the product – already on the market in Europe – high marks in the treatment of presymptomatic patients but a lesser grade in the treatment of symptomatic children.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?